This analysis of the ODYSSEY OUTCOMES trial shows that in patients with recent ACS and dyslipidemia despite intensive statin therapy, the PCSK9 inhibitor alirocumab decreased the risk of stroke, irrespective of baseline LDL-C and of history of cerebrovascular disease, over a median follow-up of 2.8 years. This evidence concerns the gene PCSK9 and metabolic syndrome.